| Overcoming Disease Progression in CLL: Evidence-Based Re-treatment Considerations | 04/09/2025 | |
| Fixed-Duration Therapy in the Relapsed/Refractory CLL Setting | 04/13/2025 | |
| Fixed-Duration vs Continuous-Dosing Approaches in CLL: Impact on QoL and Toxicity Risk | 04/11/2025 | |
| Combination Therapy in CLL: Identifying the Right Patient for the Right Treatment Approach | 04/13/2025 | |
| Combination Therapy for CLL: What Evidence Do We Have? | | |
| Frontline Fixed-Duration Therapy in CLL: Improving Outcomes and Tolerability | 04/13/2025 | |
| Fixed-Duration: A Patient-Captivating Standard of Care in CLL | | |
